Sapiens International (Delisted)
SPNS
43.45
0.00
0.00%
Sapiens International (Delisted)
US · SPNS
#2651 by market cap
Listed 1970
43.45
0.00
0.00%
Live - 5344 symbols - heartbeat 41s ago
· 2026-10-07 19:54
- Market cap
- 2.43B
- P/E (TTM)i
- 37.78
- P/Bi
- 4.73
- EPSi
- 1.29
- Div yieldi
- 0.69%
- 52W posi
- 88%
Reader sentiment
Are you bullish or bearish on SPNS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 8.71, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +5.40% YoY
Margins
- Gross margin
- 43.90%
- Operating margin
- 15.83%
- Net margin
- 13.31%
Key ratios & quality
- Enterprise valuei
- 2.26B
- PEG ratioi
- 2.48
- Altman Z-Scorei
- 8.71
PEG uses trailing P/E against the 3-year net income growth rate (15.23%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 269.19M | 289.71M | 325.67M | 382.90M | 461.04M | 474.74M | 514.58M | 542.38M |
| Gross profit | 93.52M | 109.57M | 129.52M | 155.97M | 187.84M | 200.16M | 219.59M | 238.11M |
| Selling & admin expenses | 60.56M | 52.13M | 54.27M | 69.61M | 76.34M | 75.02M | 77.25M | 85.96M |
| Research & development | 31.96M | 34.41M | 37.38M | 41.36M | 54.01M | 58.66M | 63.48M | 66.30M |
| Operating profit | 1.00M | 23.02M | 37.87M | 45.00M | 57.49M | 66.49M | 78.87M | 85.85M |
| Pretax profit | -2.01M | 19.03M | 35.10M | 41.20M | 57.29M | 65.55M | 77.12M | 89.83M |
| Tax | -2.56M | 5.03M | 8.61M | 7.04M | 9.96M | 12.62M | 14.25M | 17.51M |
| Net profit | 556.00K | 14.00M | 26.49M | 34.16M | 47.32M | 52.93M | 62.87M | 72.32M |
| Basic EPS | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Diluted EPS | 0.01 | 0.28 | 0.52 | 0.65 | 0.85 | 0.95 | 1.12 | 1.29 |
| Line item | 2024-06 | 2024-09 | 2024-12 | 2025-03 | 2025-06 | 2025-09 |
|---|---|---|---|---|---|---|
| Revenue | 136.80M | 137.03M | 134.31M | 136.11M | 141.60M | 152.32M |
| Gross profit | 60.10M | 60.30M | 60.15M | 60.66M | 61.89M | 67.31M |
| Selling & admin expenses | 21.41M | 22.10M | 21.93M | 23.19M | 26.26M | 28.37M |
| Research & development | 16.81M | 16.45M | 16.52M | 16.28M | 18.83M | 21.18M |
| Operating profit | 21.88M | 21.75M | 21.70M | 21.20M | 16.80M | 17.76M |
| Pretax profit | 22.99M | 22.66M | 22.56M | 22.53M | 18.07M | 18.00M |
| Tax | 4.38M | 4.32M | 4.70M | 4.49M | 3.68M | 3.62M |
| Net profit | 18.62M | 18.34M | 17.87M | 18.03M | 14.39M | 14.38M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.33 | 0.33 | 0.32 | 0.32 | 0.25 | 0.25 |
Balance sheet
| Line item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 130.97M | 130.01M | 147.22M | 267.36M | 300.35M | 285.31M | 314.90M | 335.14M |
| Cash & ST investments | 71.47M | 64.63M | 66.30M | 182.56M | 210.24M | 180.29M | 202.12M | 216.19M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 373.62M | 378.87M | 452.42M | 714.16M | 714.99M | 668.34M | 689.62M | 691.71M |
| Total current liabilities | 70.17M | 81.10M | 104.91M | 144.78M | 151.70M | 145.96M | 149.12M | 149.58M |
| Short-term debt | -- | 9.90M | 18.21M | 29.72M | 30.62M | 28.86M | 26.42M | 26.24M |
| Long-term debt | 78.28M | 68.58M | 58.85M | 98.68M | 78.99M | 59.28M | 39.54M | 19.79M |
| Total liabilities | 172,745,000.00 | 176,381,000.00 | 226,923,000.00 | 330,467,000.00 | 306,273,000.00 | 265,490,000.00 | 239,677,000.00 | 212,082,000.00 |
| Total equity | 200.87M | 202.48M | 225.50M | 383.69M | 408.72M | 402.85M | 449.95M | 479.63M |
| Retained earnings | -12.93M | 2.67M | 17.91M | 44.64M | 71.56M | 85.58M | 119.88M | 160.23M |
| Line item | 2024-06 | 2024-09 | 2024-12 | 2025-03 | 2025-06 | 2025-09 |
|---|---|---|---|---|---|---|
| Total current assets | 308.81M | 321.39M | 335.14M | 327.39M | 239.82M | 251.75M |
| Cash & ST investments | 186.45M | 185.95M | 216.19M | 205.86M | 74.54M | 82.20M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 667.54M | 683.30M | 691.71M | 713.98M | 739.64M | 743.69M |
| Total current liabilities | 142.78M | 147.30M | 149.58M | 194.94M | 174.69M | 166.02M |
| Short-term debt | 25.50M | 25.66M | 26.24M | 27.13M | 27.09M | 26.16M |
| Long-term debt | 19.77M | 19.78M | 19.79M | -- | -- | -- |
| Total liabilities | 207,795,000.00 | 211,987,000.00 | 212,082,000.00 | 239,643,000.00 | 227,525,000.00 | 216,498,000.00 |
| Total equity | 459.74M | 471.31M | 479.63M | 474.34M | 512.12M | 527.19M |
| Retained earnings | -- | -- | 160.23M | -- | -- | -- |
Cash flow
| Line item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 9.25M | 27.70M | 66.16M | 58.26M | 80.54M | 43.78M | 79.43M | 82.23M |
| Depreciation & amortization | 15.87M | 19.86M | 19.14M | 23.38M | 28.67M | 22.24M | 21.44M | 20.07M |
| Free cash flow | 1.06M | 20.63M | 49.02M | 47.01M | 68.69M | 34.73M | 70.16M | 72.21M |
| Dividends paid | -9.85M | -9.98M | -11.01M | -7.04M | -20.26M | -38.58M | -28.14M | -31.82M |
| Stock buybacks / issuance | -- | 0 | 0 | 108.74M | -- | -- | -- | -- |
| Ending cash balance | 71.47M | 64.63M | 66.30M | 152.56M | 190.24M | 160.29M | 126.72M | 163.69M |
| Line item | 2024-06 | 2024-09 | 2024-12 | 2025-03 | 2025-06 | 2025-09 |
|---|---|---|---|---|---|---|
| Operating cash flow | 8.55M | 13.08M | 42.11M | 25.35M | 1.87M | 10.64M |
| Depreciation & amortization | 4.70M | 5.08M | 4.65M | 4.87M | 6.11M | 6.84M |
| Free cash flow | 6.05M | 10.09M | 39.78M | 23.04M | -946.00K | 8.46M |
| Dividends paid | -- | -14.15M | -2.03M | -- | -- | 0 |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 122.65M | 146.15M | 163.69M | 143.36M | 64.54M | 82.20M |
Returns & efficiency
| Line item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 0.18 | 6.87 | 12.36 | 11.16 | 11.97 | 13.03 | 14.73 | 15.57 |
| ROA %i | 0.11 | 3.66 | 6.31 | 5.79 | 6.60 | 7.60 | 9.20 | 10.45 |
| ROIC %i | 0.38 | 5.65 | 9.06 | 8.20 | 8.90 | 10.03 | 11.42 | 12.58 |
| 5-year avg ROE %i | 7.65 | 7.41 | 8.22 | 8.21 | 8.54 | 11.08 | 12.65 | 13.29 |
| EBIT margin %i | -0.12 | 7.68 | 11.71 | 11.88 | 13.25 | 14.11 | 15.33 | 15.83 |
| FCF / sales %i | 0.11 | 7.12 | 15.05 | 12.28 | 14.90 | 7.31 | 13.63 | 13.31 |
| Current ratioi | 1.87 | 1.60 | 1.40 | 1.85 | 1.98 | 1.95 | 2.11 | 2.24 |
| Quick ratioi | 1.87 | 1.60 | 1.19 | 1.85 | 1.98 | 1.95 | 2.11 | 2.24 |
| Debt / assetsi | 20.95 | 20.71 | 26.62 | 24.81 | 20.75 | 17.44 | 12.62 | 9.22 |
| LT debt / equityi | 39.13 | 34.11 | 45.68 | 38.63 | 28.96 | 21.90 | 13.55 | 7.82 |
| Interest coveragei | -0.19 | 6.90 | 12.58 | 10.58 | 16.10 | 46.94 | -- | -- |
| Revenue CAGR (3Y) %i | 19.58 | 15.99 | 14.63 | 12.46 | 16.75 | 13.39 | 10.35 | 5.57 |
| Net income CAGR (3Y) %i | -71.02 | -11.69 | 10.72 | 357.81 | 50.69 | 26.07 | 22.73 | 15.23 |
| FCF CAGR (3Y) %i | -57.71 | -13.25 | 45.76 | 254.09 | 49.34 | -10.85 | 14.27 | 1.68 |
| Line item | 2024-06 | 2024-09 | 2024-12 | 2025-03 | 2025-06 | 2025-09 |
|---|---|---|---|---|---|---|
| ROE %i | 15.76 | 16.09 | 15.57 | 16.14 | 14.31 | 13.10 |
| ROA %i | 10.42 | 10.69 | 10.45 | 10.41 | 9.72 | 9.02 |
| ROIC %i | 13.42 | 13.76 | 12.58 | 14.42 | 11.97 | 11.82 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 15.54 | 15.63 | 15.83 | 15.90 | 14.83 | 13.72 |
| FCF / sales %i | 11.39 | 12.82 | 13.31 | 14.51 | 13.11 | 12.46 |
| Current ratioi | 2.16 | 2.18 | 2.24 | 1.68 | 1.37 | 1.52 |
| Quick ratioi | 2.16 | 2.18 | 2.24 | 1.68 | 1.37 | 1.52 |
| Debt / assetsi | 9.45 | 9.22 | 9.22 | 6.05 | 6.14 | 5.85 |
| LT debt / equityi | 8.22 | 7.96 | 7.82 | 3.49 | 3.67 | 3.38 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Insurance is the largest reported line at 96.05% of revenue, across 2 reported segments.
- The next-largest line, All other, is a distant second at 3.95% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Insurance96.05%
All other3.95%
Region
United States41.01%
Europe35.56%
United Kingdom14.17%
Rest of the world8.68%
North America0.58%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.